Stocksigma LogoStocksigma Logo

Cohance Lifesciences Receives Five USFDA Form 483 Observations for Jaggaiahpet API Facility

The USFDA completed an inspection of Cohance Lifesciences Limited's API manufacturing facility in Jaggaiahpet, Andhra Pradesh, conducted between 14th

Cohance Lifesciences Receives Five USFDA Form 483 Observations for Jaggaiahpet API Facility

Cohance Lifesciences Ltd 路 Others (Uncategorized) 路 21 Sept 2026, 5:07 pm

Cohance Lifesciences Receives Five USFDA Form 483 Observations for Jaggaiahpet API Facility The USFDA completed an inspection of Cohance Lifesciences Limited's API manufacturing facility in Jaggaiahpet, Andhra Pradesh, conducted between 14th Sep'26 and 19th Sep'26. The audit concluded with the issuance of a Form FDA 483 with five observations. In response, the company has initiated corrective and preventive actions (CAPA) and plans to submit its formal response to the regulator within the stipulated timeline.

Original exchange filing (PDF)

More announcements from Cohance Lifesciences Ltd

All Cohance Lifesciences Ltd announcements